openPR Logo
Press release

Essential Tremor Pipeline: Advancing Neuromodulation and Targeted Therapies to Transform Essential Tremor Treatment | DelveInsight

05-14-2025 03:28 PM CET | Health & Medicine

Press release from: DelveInsight

Essential Tremor Pipeline

Essential Tremor Pipeline

The treatment landscape for Essential Tremor (ET), a prevalent neurological movement disorder characterized by involuntary rhythmic shaking, is undergoing a significant evolution. Historically managed with beta-blockers, anticonvulsants, or surgical interventions like deep brain stimulation (DBS), current research is moving toward more targeted, disease-modifying approaches. Biopharma companies are actively exploring novel mechanisms, including GABAergic modulation, T-type calcium channel blockers, and neurostimulation technologies to deliver more effective and personalized care.

DelveInsight's "Essential Tremor - Pipeline Insight, 2025" offers a comprehensive analysis of the global R&D landscape, spotlighting clinical and preclinical therapies that aim to address the root neurophysiological dysfunctions of ET. The report features promising candidates such as Ioflupane 123I, PRAX 114, and TD 567, as well as ongoing research programs targeting the thalamocortical circuitry and tremor pathophysiology.

It also examines advances in drug delivery systems, non-invasive neuromodulation devices, biomarker-guided treatment strategies, regulatory support, and strategic collaborations driving innovation. As unmet needs remain high in this underserved market, this report highlights the transformative pipeline developments shaping the future of essential tremor management.

Interested in learning more about the current treatment landscape and the key drivers shaping the essential tremor pipeline? Click here: https://www.delveinsight.com/report-store/essential-tremor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Essential Tremor Pipeline Report
• DelveInsight's essential tremor pipeline analysis depicts a strong space with 7+ active players working to develop 10+ pipeline drugs for essential tremor treatment.
• The leading essential tremor companies include Merz Pharma, SAGE Therapeutics, GE Healthcare, Praxis Precision Medicines, OB Pharmaceuticals, Novartis, Jazz Pharmaceuticals, and others are evaluating their lead assets to improve the essential tremor treatment landscape.
• Key essential tremor pipeline therapies in various stages of development include Botulinum toxin A, Zuranolone, Ioflupane 123I, PRAX 114, TD 567, Research programme: epilepsy and essential tremor therapeutics, SAGE 324, Rimtuzalcap, Suvecaltamide, and others.
• In February 2025, Praxis Precision Medicines shared an interim update from Study 1 of its Essential3 program evaluating ulixacaltamide for essential tremor, along with progress on other pipeline therapies and financials.
• In November 2024, Insightec received both FDA approval and CE Mark for its Exablate Prime system, now compatible with Philips MRIs, expanding access to non-invasive focused ultrasound treatment for ET and Parkinson's disease.
• In August 2024, Medtronic became the first company to gain FDA approval for performing deep brain stimulation (DBS) surgery for ET and Parkinson's disease while patients are asleep under general anesthesia.

Request a sample and discover the recent breakthroughs happening in the essential tremor pipeline landscape @ https://www.delveinsight.com/report-store/essential-tremor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Essential Tremor Overview
Essential tremor is a chronic and progressive neurological disorder primarily characterized by a 4-12 Hz kinetic tremor, tremors that occur during voluntary actions such as eating or writing. While it most commonly affects the hands and arms, it can progressively extend to the head, voice, jaw, and other body parts. Due to its varied causes, clinical manifestations, treatment responses, and underlying pathology, growing evidence suggests that ET may represent a group of related disorders rather than a single condition. This has led to the emerging view that the term "essential tremors" may better capture its clinical complexity.

Find out more about essential tremor medication @ https://www.delveinsight.com/report-store/essential-tremor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Essential Tremor Treatment Analysis: Drug Profile
SAGE-324: Sage Therapeutics
SAGE-324, developed by Sage Therapeutics, is an oral investigational neuroactive steroid that acts as a positive allosteric modulator (PAM) of GABAA receptors. It targets both synaptic and extrasynaptic GABAA receptors to enhance GABAergic inhibitory signaling, crucial for regulating neuronal activity. Since GABA dysfunction is linked to the development of essential tremor (ET), SAGE-324 is being explored as a potential treatment and is currently in Phase II clinical development.

Learn more about the novel and emerging essential tremor pipeline therapies @ https://www.delveinsight.com/report-store/essential-tremor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Essential Tremor Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

By Molecule Type
• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Scope of the Essential Tremor Pipeline Report
• Coverage: Global
• Key Essential Tremor Companies: Merz Pharma, SAGE Therapeutics, GE Healthcare, Praxis Precision Medicines, OB Pharmaceuticals, Novartis, Jazz Pharmaceuticals, and others.
• Key Essential Tremor Pipeline Therapies: Botulinum toxin A, Zuranolone, Ioflupane 123I, PRAX 114, TD 567, Research programme: epilepsy and essential tremor therapeutics, SAGE 324, Rimtuzalcap, Suvecaltamide, and others.

Dive deep into rich insights for drugs used for essential tremor treatment; visit @ https://www.delveinsight.com/report-store/essential-tremor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Essential Tremor Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Essential Tremor Pipeline Therapeutics
6. Essential Tremor Pipeline: Late-Stage Products (Phase III)
7. Essential Tremor Pipeline: Mid-Stage Products (Phase II)
8. Essential Tremor Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Essential Tremor Pipeline: Advancing Neuromodulation and Targeted Therapies to Transform Essential Tremor Treatment | DelveInsight here

News-ID: 4016130 • Views:

More Releases from DelveInsight

Candidiasis Clinical Trials Analysis 2025: Oral Agents, Next-Generation Echinocandins, and Broad-Spectrum Antifungals Targeting Recurrent and Invasive Disease | DelveInsight
Candidiasis Clinical Trials Analysis 2025: Oral Agents, Next-Generation Echinoca …
DelveInsight's "Candidiasis - Clinical Trials Analysis, 2025" examines an active clinical landscape addressing both mucosal (vulvovaginal) and invasive candidiasis. Unmet needs for safe, oral, and resistance-resilient therapies have driven the development of therapies across multiple modalities - new oral triterpenoids and azoles for recurrent vulvovaginal candidiasis (RVVC), next-generation echinocandins for candidemia/invasive candidiasis, and first-in-class broad-spectrum agents for drug-resistant and systemic infections. Regulatory progress and late-stage trials over the past few
Necrotizing Enterocolitis Clinical Trials Analysis 2025: Probiotics, HMOs, and Regenerative Therapies Advance Prevention and Care | DelveInsight
Necrotizing Enterocolitis Clinical Trials Analysis 2025: Probiotics, HMOs, and R …
DelveInsight's "Necrotizing Enterocolitis (NEC) - Clinical Trials Analysis, 2025" highlights an evolving pipeline aimed at reducing NEC incidence and severity in preterm infants. With NEC remaining a leading cause of neonatal morbidity and mortality, clinical studies are shifting toward microbiome-based prevention, human milk-derived biologics, and regenerative approaches. Probiotic regimens containing Bifidobacterium and Lactobacillus strains are showing consistent efficacy in lowering NEC rates and mortality, driving wider adoption in NICUs. Parallel trials
Brain Hemorrhage Clinical Trials Analysis 2025: Hemostasis, Neuroprotection, and Minimally Invasive Evacuation Strategies Advance Acute Care | DelveInsight
Brain Hemorrhage Clinical Trials Analysis 2025: Hemostasis, Neuroprotection, and …
DelveInsight's "Brain Hemorrhage - Clinical Trials Analysis, 2025" surveys an active acute-care landscape focused on reducing hematoma expansion, limiting secondary injury, and improving functional recovery after intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). Trials increasingly pursue rapid hemostatic agents, targeted neuroprotectants, and device-based minimally invasive clot evacuation to shorten disability and lower mortality. Hemostatic and anti-expansion strategies (reversal agents, factor concentrates, and novel transferrable hemostats) aim to stabilize patients early and
Cachexia Clinical Trials Analysis 2025: Metabolic Modulators, Anabolic Therapies, and Anti-inflammatory Approaches Aim to Restore Mass and Function | DelveInsight
Cachexia Clinical Trials Analysis 2025: Metabolic Modulators, Anabolic Therapies …
DelveInsight's "Cachexia - Clinical Trials Analysis, 2025" examines a diverse development landscape targeting the complex metabolic, inflammatory, and neurohormonal drivers of cancer- and disease-related wasting. Given cachexia's strong association with poor survival, treatment intolerance, and reduced quality of life, trials increasingly measure both anabolic endpoints (lean body mass, muscle strength) and patient-centered outcomes (physical function, fatigue, appetite). Late-stage and registration-enabling programs span ghrelin agonists and appetite stimulants, selective androgen receptor modulators

All 5 Releases


More Releases for Essential

Essential Oils Industry Overview 2025: Growth, Challenges, Opportunities | Top 5 …
DataM Intelligence has published a new research report on "Essential Oils Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Sample PDF Of This Report (Get
Lemon Essential Oil Market to See Huge Demand by 2030: Young Living Essential Oi …
The latest study released on the Global Lemon Essential Oil Market by HTF MI Research evaluates market size, trend, and forecast to 2030. The Lemon Essential Oil market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the
Organic Essential Oils Market Is Booming Worldwide | Plant Therapy, Young Living …
A Latest intelligence report published by Market Research Forecast with title Global Organic Essential Oils Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Organic Essential Oils market. This report provides a detailed overview of key factors in the Global Organic Essential Oils Market and factors such as driver, restraint, past and current trends, regulatory scenarios and technology development. Definition: The Organic
Essential Oils Market Is Booming Globally with doTERRA, Young Living Essential O …
This Essential Oils Market report brings into focus plentiful of factors such as the general market conditions, trends, inclinations, key players, opportunities, and geographical analysis which all aids to take your business towards the growth and success. This Essential Oils Market report provides the broader perspective of the market place with its comprehensive market insights and analysis which eases surviving and succeeding in the market. Moreover, Essential Oils Market report
Lemongrass Oil market Key Development Trends; Top Players; Young Living™ Essen …
QY Research Groups details out informative data related to the global Lemongrass Oil market which anticipated to garner major market share. This Research Report provides the newest realistic data useful for future worldwide business trend This report studies the global Lemongrass Oil market status and forecast, categorizes the global Lemongrass Oil market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North
Global Essential Oil Market 2017 Forever Living, Essential Oil, Moksha Lifestyle …
Essential Oil Market Research Report A market study based on the " Essential Oil Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Essential Oil Market 2017’. The research report analyses the historical as well as present performance of the worldwide Essential Oil industry, and makes predictions on the future status of Essential Oil market on the basis of this analysis. Ask For Sample